Intravenous adenosine: Continuous infusion and low dose bolus administration for determination of coronary vasodilator reserve in patients with and without coronary artery disease  by Kern, Morton J. et al.
718
	
[ACC V .I . Is. No. 3
Sepwmhcr 1111 :711121
METHODS
Intravenous Adenosine: Continuous Infusion and Low Dose Bolus
Administration for Determination of Coronary Vasodilator Reserve in
Patients With and Without Coronary Artery Disease
MORTON J . KERN . M D. FACC. UBEYDULLAH DELIGONUL, MD,
SATYANARAYAN A TATINENI, MD, HARVEY SEROTA, MD . FACC,
FRANK AGUIRRE, MD, FACC, THOMAS C . HILTON, MD
Sl . Lnui.y, Mis:vouri
To assess the use of adenosine as an alternative agent for deter
mination of coronary vasodilator reserve, hemodynamics and
coronary blood flow velocity were measured at rest and during
peak hyperemic responses to continuous intravenous adenosine
infusion 1511, 100 and 150 pg/kg per min for 3
min) and intracor
onary papaverine (IO mg) in 34 patients (17 without [group 11 and
17 with [group 21 significant left coronary artery disease), and in
17 patients (11 without and 6 with left coronary artery disease)
after low dose (2 .5 mg) intravenous bolus injection of adenosine .
The maximal adenosine dose did
not change mean arterial
pressure t10 ± 14% and 6 ± 12% for groups I and 2,
respectively) but increased the heart rate (15 t 18% and 13 t
16%, respectively). For continuous adenosine infusions, mean
coronary flow velocity increased 64 ± 100%, 122 ± 94% and
198 t 59% and 15 t 51% 110 t 95% and 109 t 86% in groups
I and 2, respectively for each of the three
doses . Mean coronary
flow velocity increased significantly after 100 and 150 #g/kg of
adenosine and 10 mg of intracoronary papaverine (48 ± 25, 52 ±
19 and 54 ± 21 cm/s, respectively ; all p < 0.05 vs. baseline) and
was significantly higher than in group 2
137 ± 24 .32 t 16, 41 ±
23 cmls; all p < 0 .05 vs . group 1) . The coronary vasodilator
reserve ratio (calculated as the ratio of hyperemic to basal mean
Determination of coronary blood flow velocity reserve is a
commonly accepted
method for assessing functional re
sponses to both physiologic and pllannacologic stimuli in
patients with and without coronary atherosclerotic disease
I131 . Intracoronary papaverine is the most
widely used
agent, producing maximal coronary hyperemia with signifi
cant QT prolongation (4) . Because of episodic occurrences
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flow velocity) for adenosine and papaverine was 2 .94 ± 1 .50 and
2.94 ± 1 .00, respectively, in group I and was significantly and
similarly reduced in group 2 (2.16 ± 0.81 and 2.38 ± 0,78,
respectively; both p < 0 .05 vs, group 1)
. Low dose bolus injection
of adenosine ilxreased mean velocity equivalently to that after
continuous infusion of 100 pg/kg, but less than after papaverine.
There was a strong correlation between
adenosine infusion and
papaverine for both mean coronary flow velocity and coronary
vasaditntor reserve ratio (r r = 0 .871 and 0.325; SEE = 0 .068 and
0 .189, respectively ; both p < 0,0005) .
No patient had significant arrhylhmias or prolongation of the
corrected QT (QTc) interval with adenosine, but papaverine
increased the QTc interval from 445
t 44 to 501 t 43 ms p <
0 .001 vs. both maximal adenosine and baseline) and produced
nonsustained ventricular taehycardia in one patient .
These data indicate that intravenous adenosine in doses
> 100 jug/kg (and in low dose bolus injections) for most patients is
nearly equivalent to intracoronary papaverine without producing
QTc prolongation, making this agent a potentially superior and
safer alternative to inD acoronary papaverine for determination of
coronary vasodilator reserve.
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of severe ventricular arrhythm ;as requiring immediate car
dioversion (58), alternative pharmacologic stimuli for cor
onary vasodilator reserve are dasfroble
. Intracoronary aden
osine has been used recently (9 .10) and induces maximal
coronary hyperemia similar to that of intracoronary papav
erine (4). However, the induction of complete heart block
and severe bradycardia with a variable dose response re
ported in earlier studies (9f has limited wide application of
intracoronay adenosine
. Conversely, intravenous adeno
sine also produces significant if not equi"alent hyperemia
comparable with that of other coronary vasodilators but
without QT prolongation or heart block in doses <200 pg/kg
body weight (1113) . Compared with dip, ridamole, intrave
nous adenosine has an additional advantage of being a very
shortacting drug . Prominent but transient side effects of
facial flushing and chest discomfort resolve within seconds
of
termination of adenosine infusion (14) .
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This study tested the hypothesis that coronary hyperemia
induced by intravenous infusion or bolus injection of aden
osine would he equivalent to that produced byintracoronorv
papaverine without QT
prolongation ar induct or of sign,
heart conduction disturbances
. These dirt anuld provide
the basis fur use of this agent in patients with a high likeli
hood of
an adverse response to intracuronary papaverine ur
in whom
an intravenous rather than intracoronarv drue
administration for hyperemia
stimtiialion would hc dcSir
able .
Table l . Clinical Characteristics of the 34 Study Patient
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dial infarction 1~~72 hl, unsuitable anatomy (for example .
significant left main coronary inicry narrowing), valvulat
heart disease . congestive heart failure or left ventricular
ejection fraction 60% acre cscluded . Five patients in
group I had isolated right coronary artery disease : two
arteries were totally occluded . Font patients in group 2 with
angjographic collateral flow to the h u occluded left coro
nary :inters score included . In group I, two patients were
receiving a betaadrenergic blocker and four patients a
calcium channel Mocker: three patients (Cases 13. 15 and 16)
had tutle!gone cardiac transplaouuiott . respectively . I . 2
and 3 years previously and were receiving cyclosporine and
azathioprine . In group 2, 8 patients were receiving a beta
Mocker and I I patients a calcium channel blacker .
Hetaadrenergic blocking drugs, calcium channel antago
nists and longacting nitrates were not withheld for this
study. Diphenhydramine (25 mgt and diazepam (2.5 mg)
were given orally as routine precalheterization medications
to all patients . No sublingual or intracoronary medications
were given until the initiation of the study ; heparin . 5.000 U .
was given intravenously after insertion of the coronary
catheters. The research protocol was approved by the Hu
man Subjects Committee of the Institutional Review Board
at St . Louis University Hospital . All patients gave informed
written consent in accordance with guidelines established by
the Human Subjects Committee .
Erpc'rirneatal Protocol
The study protocol was designed to measure coronary
blood flow velocity responses to intracoronary papaverine and
three doses of adenosine administered by continuous intrave
nous infusion and intravenous low dose bolus injection .
Coronary blood flow velocity, measurements . After diag
nostic coronary angiography and left ventriculography, cor
onary blood flow velocity was measured with use of an 8F
Judkinsstyle Doppler catheter lCordis Corporation) with a
20MHz Doppler crystal implanted in the lip as previously
described and validated (I5) . 5nis nonselective intracoro .
nary velocity catheter was used in all but two patients it
whom whselective intracoronary flow velocity was mea
sured with a 3F Doppler catheter (DC101 . Millar Instru
ments) 13)
. The Doppler catheter was positioned within a
proximal normal left coronary artery segment before the
large branch bifurcation, This location was maintained con
slant throughout the study period
. Doppler data were proc
essed with a zero cross velocimeter (Millar Instruments)
from which mean and phasic velocity signals were obtains .
The Doppler coronary flow velocity and hemodynamic sig
nals were displayed and recorded on a photographic multi
channel oscillographic recorder (Electronics for Medicine,
VR12) . Mean and phasic Doppler velocity signals were
calibrated front the velocimeter before catheter placement
from an internally set arbitrary 0 to 100cmls signal for full
scale deflection .
After stable baseline signals were obtained, 10 mg of
tICC set
IS . Nn . I
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papaverine was injected into the left coronary artery over
I to '
s with continuous data recording through the peak
hyperemic period and for 60 to 120 s later . In 10 patients.
after return to the control state . a second duplicate to to
12mg papaverine injection was also performed . After
?3 min of equilibration to baseline values, adenosine
(5 mg'ml. AB Hassle) was infused into the femoral vein by a
controlled pump (Harvard Apparatus) to deliver 50, 100 and
150
µg/kg
body weight per min . each dose given over 3 min .
Data were recorded al the end of each dosing interval, after
which the next dose was initiated. The time to onset of
hyperemia and offset of maximal hyperemia was recorded .
The order of adenosine and papaverine administration was
reversed in 18 patients .
In 17 patients (11 in group I and 6 in group
2),
a 2 .5mg
bolus injection of adenosine was given through a femoral
(n = 14) or brachial (n  3) vein . with continuous hemody
namic data recording . A second bolus dose of 5 mg was
given in nine patients . In 19 patients (8 in group I and I1 in
group 2) . pulmonary artery pressures were measured during
coronary hyperemia with a fluidfilled balloontipped cathe
ter positioned from a femoral vein .
In 30 patients, a 12lead electrocardiogram (ECG) was
obtained al baseline and at peak hyperemia for each dose of
adenosine and papaverine . From the 12lead ECG obtained
at rest and at peak hyperemia, the QT interval was measured
and corrected with Bazett's formula . An ST segment depres
sion was reported when the ST segment shift was >0 .5 mV
from baseline . New T wave inversion or T wave flattening
occurred in two patients. The duration of seconddegree
heart block was measured from the continuous lead II ECG
recording during hemodynamic data collection .
Coronary angiographic measurements . To assess changes
in coronary dimension during adenosine infusion, a left
coronary cineangiogram (20' right anterior oblique projec
tion) was obtained at baseline and at peak hyperemia in 10
patients . The developed cineangiographic films were pro
jected on a General Electric CAP12 projector. Digital com
puterassisted calipers (Sandhill Scientific) were used to
measure the arterial segment 5 to 10mm distal to the
velocity catheter tip and in the mid left anterior descending
artery distal to the circumflex artery bifurcation . The BE
velocity catheter diameter (2 .67 mm) was used as a scale
factor for absolute dimension calculations in millimeters .
Angiography was not performed during papaverineinduced
hyperemia. Overestimation of vasodilator reserve of approx
imately 169'e with papaverineinduced vessel diameter en
largement has been previously reported (16) .
Coronary velocity signal analysis. Coronary artery veloc
ity signals, both phasic and mean, were recorded at both a
IP and a 100mm's
paper speed and digitized on an offline
microcomputer system . The diastolic flow velocity integral
svos obtained by planimetry of the area under the diastolic
velocity signal from the aortic dicrotic notch to the systolic
aortic upstroke as previously reported (171 . The total time of
diastolic flow velocity and time to maximal phasic
flow
velocity were also measured .
Coronary vasodilator reserve ratios. The coronary vaso
dilator reserve ratio was computed as the ratio of peak
hyperemic flow to basal mean flow velocity . A coronary artery
resistance index was computed as the quotient of mean arterial
pressure and mean coronary velocity . An additional index of
coronary vasmlilalor response normalized for mean arterial
pressure was computed as (Hyperemic mean vcloeiryl
Hyperemic mean arterial pressure)/(Basal mean velocity)Basal
mean arterial pressure). The percent increase from baseline
value was also computed as [(Peak
 BasagiBasall
x 1610
.
Duplicate coroearv responses to intravenous adenosine
and intracoronary papaverine were obtained in 10 patients .
The reproducibility
of
coronary flow
velocity values over the
study periods was within 010%
.
Statistical method . Each patient served as his or her own
control
. Data were analyzed by oneway analysis of variance .
When results or analysis of variance were significant . mean
values were compared by utilizing Duncan's multiple range F
statistic (18) and, where appropriate . paired and nonpaired
Student's r tests were performed . Simple linear regression was
used for correlation coefficients in comparing coronary flow
velocity after adenosine and papaverine . Statistical significance
was accepted as p < 0.05 . Results or. expressed as mean
values ± I SD unless otherwise indicated .
p < 0.05 veesasgroup 2
: 'p < 0
.05 versus
treed so
. VUlue .are mean , alue, o I SD. A =
n 1511
oa'kn o@Jrnoxinn. CAD  2 1„ith .oronuq
artery disease)
; Dia = diastolic pressure Imm Her: HR = heart rate
heat, nliw . HRS15 = heart rulepressure product
Iis. HFbeel min ') :
MAP = ,;
arsenal pressureImmHgl ;NL=groupI(withoutcoronary'anewdis0,eI :P=papaletlne :Pa,, .Ppuln170 motendteao0c1D1:mdsys1olicIS) prc .,ure~
(mm Hg) : `k4  percent change : Sys = systolic
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Results
Sysrc•r elic' Heerrodrnarnic Responses (Table 2)
Adenosine infusion versus intravenous papaverine . Aden
osine infusion did not statistically decrease mean arterial
pressure in either patient group. Papaverine decreased mean
arterial pressure ( 105 ' 12 vs . 95 ' 11 mm ft p < 0,05) in
group l
. The respective relative reductions in mean arterial
pressure for groups I and 2 during adenosine 110
.
147
and 6 '
C7) and intracoronary papaverine
I10
 7%
and 8 s 7 rl were similar, Heart rate increased (15 * 187)
during 150 pglkg adenosine infusion 176
.
11 to 87 x
14 heatstmin ; p < 0 .051 in group I . The heart ratesystolic
pressure product was unchanged . Adenosine did not in
crease pulmonary artery pressure in either patient group .
Adenosine bolus injection (Table 3). Low
dose (2 .5 mg)
bolus injection of adenosine did not reduce mean arterial
pressure (107  17 to 95  16 mm Hg;
p = NS) . Five mg
of adenosine decreased mean arterial pressure from 107 * 9
to 93 x 12 (p < 0 .05). Heart rate was unchanged during 2.5
or 5mg adenosine bolus injection
. The percent change in
mean arterial pressure and heart rate was similar for the
two adenosine doses . The 5mg bolus responses were dif
ferent from those during continuous adenosine infusion
(100 pglkg per min) and intracoronary papaverine adminis
tration.
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Table 2
. Hemndynamlc Data During Intravenous Adenosine :md Imc¢urona.ry Papon,
Adenarirn <yerkgl Papa'at,
Dateline 50
	
100
1511 In,
H} pcr .m
u
up
Sot
NL 137 * 16 140 15 132 a 20
1
:2  26
11x,'1
1472 .1i 8 7
CAD 142 » 16
145 x 16 139 x 20
178  '6
N'_1  C714` 911 In9
Dia
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80 c 11 75  15  .  I1   Y I4
I6 II

:I
CAD 76 *10 7710 72214
6X16
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9^_
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
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CAD 72 » 15
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3e
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32'10
28 :7 11x9 14 :' 3612 14vL
16'6

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Table 3. Hemodynamic and Coronary Flow Velocity Data During Adenosine Bolus Injection . Adenosine Infusion and
Intrscoronary Papaverine
Data presented in the subset of 17 patients all receiving adenosine infusion, adenosine bolus injection and papaverine
:9of the 17 patients received a second
bolosinjeclionof5ntgofadenosine,'p00.05versusbzseline:Act) =adnr inlraven0usinfusionD0004(68permin) :A2 .S=adcnasiueinlnvenousbolus
injectoo 12
.5 mgt : A5 = adenosine intravenous bolus injection IS mgt . CVRsoronary vasodilarnr reserve ratio
: DVF, = diastolic now velocity inmgral
MV = mean flow velocity (cmhl : PAP  intracoronary papaverine 110
mgt :
PV = peak phasic flow velocity (am(s): other abbreviations as in Table 2 .
Coronary Flow Velocity Responses (Table 4)
Adenosine infusion. In group I , adenosine infusions of50 .
100 and 150
µg/kg
increased mean coronary flow velocity to
30 .3_ 20 .4, 47 .6 . 24.6 and 51,7 ± 18.6 cm/s, respectively .
Papaverine increased mean flow velocity to 53 .5 ± 20.7 cm/s
(p  NS vs . 100 and 150
µg/kg
of adenosine) . In group 2,
adenosine infusion increased mean flow velocity
20
.1 ± 12 .7,
37 .9 ± 24 .4 and 32.4 ± 16 .1 curls, respectively ; after
papaverine, it increased to 40 .6 ± 22 .6 cm/s (p < 0.05 vs .
group I for both adenosine [100 and 150 µgikg] ane pt:pav
erine) (Fig.
1) .
For adenosine infusion and papaverine, the relative in
creases in mean coronary velocity were similar (198 ± 147%
and 176 ± 69%, respectively, in group 1 ; 109
.
86°/( and
168 ± 109% .
respectively, in group 2; both p = NS) . The
Table 4 .
Coronary Flow Velocity Data During Intravenous Adenosine and Inlracoronary Papaverine
vasodilator responses to adenosine (at both 100 and
150
µg/kg)
were similar before and after papaverine admin
istration
. Similar increases reflecting augmented coronary
blood flow were present for diastolic flow velocity integral,
peak phasic velocity, coronary reserve index and coronary
vasodilator reserve normalized for mean arterial pressure
.
Figure 2 and Table 5 show correlations of mean coronary
flow velocity responses to adenosine and papaverine .
The maximal flow velocity response to adenosine oc
curred after 50 µg/kg in two patients in group 1 . after
100 µgikg in six and nine patients in groups I and 2,
respectively, and after 150 µgikg in eight patients in both
groups . One patient (Case 27) in group 2 had only a minimal
response to > 150 or 200
µg/kg
of adenosine, despite marked
hyperemia with papaverine .
'p < 0 .05 versus group 2:
tp
< 0 .05 versus baseline . Values arc mean values 0 I SD
. CVR, = coronary vasodilator reserve index : CVR„ = coronary
vasodilator reserve ratio normalized for mean arterial pressure: other abbreviations as in Tables 2 and 3.
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Figure 1 . Mean coronary flow velocity (cm/s) during adenosine and
papaverine (PAP( administration in the normal (NL) .subjects (group
II and patients with left coronary artery disease ICADI (group
2_) .
Hyperemic values for papaverine were significant for both groups .
	p
< 0
.05 versus baseline .
Adenosine bolus injection . Low dose (2 .5 mg) bolus in
jection of adenosine increased mean flow velocity (58 t
23 cmls) similar to both adenosine infusion (100 ggikg per
min, 60 t 30 curls ; p = NS) and papaverine (60 ± 30 cmis,
p = NS) . Because of the decrease in mean arterial pressure
after a 5mg bolus injection, the hyperemic mean velocity
(49 ± 22 cm/s) increased less than after the 2 .5mg bolus
injection
. Of the nine patients receiving a 5mg bolus injec
tion of adenosine, only two had augmentation of mean flow
velocity above values for a 2 .5mg bolus injection . Two
patients had transient seconddegree heart block with pauses
4 s
. Among patients receiving the low dose (2 .5 mg) bolus
injection, one patient had transient heart block (<2 s) that
did not delay the time to maximal hyperemia.
Timing ofhyperemic responses . The peak coronary hyper
conic effect induced by adenosine for both low dose bolus
injection and continuous infusion (>100 gglkg) occurred at
20
t
25 s (range IS to 40). The offset of effect occurred at
45 t 20 s . The peak hyperemic papaverine responses,
similar to previously published data (4 .16,17) . occurred
between 20 and 35 s, with return to baseline values within
120s.
There were no significant differences with respect to total
time of diastolic flow velocity (0 .50 t 0 .10 s). lime to peak
phasic velocity (0.16 t 0 .08 s) . first third of the diastolic flow
velocity integral (36 ± 5%) and first half of the diastolic flow
velocity integral (57 t 57c) for the various doses of adeno
sine or papaverine .
Coronary Vasodilator Reseroe Ratios (Table 5)
Adenosine infusion versus papaverine (Fig . 3 and 4). The
coronary vasodilator reserve ratio in group I for adenosine
(50. 100 and 150 gglkg) was 1.67 t I
.D), 2
.51 ± 0 .94 and
2
.94 ± 1 .50, respectively ; for papaverine, it was 2 .94 t 1
.00 .
In group 2 . the ratio was 1 .09 t 0 .47 .2 .14 t 0.91 and 2.16 *
0 .81,respectively (p < 0.05 for 50 and 150 gglkg of adeno
sine)
; after papaverine, it was 2.38 .cc 0.781p < 0 .05 vs . group
I) . When using the maximal adenosine response, the coro
nary vasodilator reserve ratio after adenosine was 3 .16 ±
Can
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Figure 2. Correlation of mean coronary flow velocity responses to
papaverine and three different doses of adenosine . The normal
subjects (ND (group II are shown by circles : the patients (with
coronary artery disease ICADI (group 2) are indicated by triangles.
1 .36 and 2.28 ± 0 .80 for groups I and 2 . respectively (p <
0 .01) .
.Adenosine bolus (Fig. 5) . The coronary vasodilator re
serve ratio for a 2.5mg bolus injection of adenosine was
2 .17 t 0 .91, which was less than that after papaverine
(2 .47 ± 1 .32 ; p < 0.05) but equivalent to that after infusion of
adenosine 12 .27  0 .73 : p = NS) The coronary ree ratio
for the nine patients receiving a 5mg bolus injection of
adenosine was 2.07 t 0
.05, which was significantly less than
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Table 5. Comparison of Adenosine and Papaverine Coronary
Flow Velocity Responses
2.5 mgt
A  adenosine : P  papaverine .
that after both papaverine and the continuous adenosine
infusion 1100 tuglkg per min) .
.A reduced (<2 .5) coronary reserve ratio saggesrive of
rnicrocircalatorv abnormalities was present in six patients in
group 1 . During adenosine infusion, chest pain or fullness
was reported in 9 of 17 patients in group I and 7 of 17
patients in group 2 . Adenosine was associated with new ST
segment depression in four and five patients in groups I and
2, respectively .
Coronary angiographic responses
. Hyperemia during
adenosine infusion did not increase the absolute angio
graphic coronary luminal diameter in either group of pa
tients . There was no increase in the proximal epicardial
vessel diameter (control 3 .72 0 0.991o 3 .72 ± 0 .86 mm after
adenosine
; percent change I ± 6%0) compared with the and
and distal segments (3 .39' 0 .85 vs . 3 .35 ' 0 .98 mm ; percent
change 1 ± 12%) during adenosine infusion .
Figure 3
. Coronary vasodilator rc,vrve (CVRI ratios for adenosine
(valid burst and papaverine (open bars) for both the normal (NL) and
coronary artery disease (CAD) groups . "p < 0 .05 versus values in
the normal group.
5~
4
a
CVR (units)
0
CAD
s~
51
Min Mal
,
,
Adenosine
CVR (units)
JACC Vul. Ia . Na . t
Scplcmbcr 1711
:71829
•
LAD•
 3i5
z Papaverine
CVR (units)
Figure 4
. Correlation for individual coronary vasodilator reserve
ICVR) values between maximal adenosine and papaverine . Abbre
viations as in Figure I .
ECG responses to adenosine and papaverine (Fig . 6) .
Papaverine, but not adenosine, increased the QTc interval
(445 ± 44 to 501 ± 43 ms after papaverine ; p < 0 .01 vs .
baseline and p < 0.05 vs. adenosine ; 462' 61 to 455 ± 47 ms
after maximal adenosine
; p = NS) . There were no significant
alterations in PR, QRS or RR intervals with either agent .
Figure 6 shows the hemodynamic and flow velocity signals
typically obtained during adenosine and papaverine admin
istration in the same patient
. Adenosine produced no ECG
changes, whereas papaverine increased the QTc interval and
induced brief nonsustained runs of ventricular tachycardia in
one patient in group 2 .
Transient (<2s pauses) sets nddegree heart block oc
curred in four patients recei .ing 150 pglkg per min of
adenosine and one patient with a 2 .5mg bolus injection (Fig .
7)
. These brief periods spontaneously resolved arid did not
recur before cessation of the adenosine infusion . No patient
required atropine or temporary pacing or had a complication
requiring premature study termination
.
Discussion
Coronary flow velocity responses to intravenous adenosine .
Adenosine has been widely used in studies of the coronary
circulation in animals . Until recently, its safety and dose
response characteristics in patients, especially those with
coronary artery disease, have not been defined
. The current
study confirms a dose range for continuous intravenous
infusions and demonstrates that low dose bolus administra
tion effectively produces increases in coronary blood flow
OrenRSien Line
r p VmAn SEE K 61opr Inlereepl
Corunare anvodilamr rescrvc
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Figure 5. Left. Correlation for individual coronary vasodilator re
serve (CVR) values between bolus doses of adenosine and papav
erine. Right, Correlation of mean coronary low velocity responses
for adenosine and papaverine_
velocity in a manner comparable with that of the existing
standard, intracoronary papaverine . These data are similar
to those of Wilson et al. (10) and extend their observations
by examining patients with coronary artery disease and the
effects of low dose bolus adenosine administration . Wilson
et al . (10) indicated that coronary blood flow velocity and
vasodilator reserve ratio (4.6  0.3) were maximal at an
intracoronorv dose of 12 gag of adenosine and were equiva
lent to that after papaverine (4 .8 ± 3) . Intravenous adenosine
in doses of 70, 100 and 140 (agikg per min produced a
coronary vasodilator reserve ratio of ?9 = 6 .4.5  0.7 and
4
.4 _ 0 .5, respectively, which was comparable with that
after intracoronary papaverine
. with similar maximal
changes in arterial pressure ( I I = 3 mm Hg) and heart rate
KFRK ET as
NDVNI)s,SE FVPCORONARY vnsQDiLnToxREsFRvT
PepaveMm
Mean Coronary Ftow Velocity
issec)
za ~^ Ar, (2.5 o  .1)
Mean Coronary Flow twinnity, (eeaisec)
120
zo m
'0
adenoslno, t25mg ballet
Mean Coronary Flow Velocity (cmisec)
nn n
P.p.in
.
S
(18 3 beatsiminl . In the current study with slightly higher
intravenous adenosine doses, similar flow velocity and he
modynamic responses for patients without coronary artery
disease were demonstrated . The absolute values of mean
flow velocity and coronary reserve ratio differed . most likely
because of differences in velocity catheter techniques and
patient characteristics
.
Adenosine as an alternative to papaverine . The ultrashort
blood halflife of adenosine results in complete disappear
ance of hyperemic effects and drugassociated sensations
within minutes of termination of infusion . Serious complica
tions found with papaverine should therefore never develop .
Although transient heart block was observed at the highest
doses in four patients, adenosine did not cause significant
alteration of ECG intervals . The episodes of heart block
were usually <2 s in duration, sporadic and immediately
(<45 s) abolished with termination of infusion . Papaverine
caused consistent QT prolongation and one episode of
ventricular tachycardia . These findings, confirmed by others
(58) and especially prominent in women with a slow heart
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rate, suggest caution for the continued general use of papa
verine . Low dose bolus adenosine injection was similar to
continuous infusions and would be useful for repetitive rapid
assessment of coronary flow responses before and during
interventions when intracoronary administration would not
be suitable .
Limitations to the use of intravenous adenosine may
occur in patients with bronchospastic pulmonary disease or
those with arterial hypotension or high degree atrioventric
ular (AV) block . Adenosine may also be contraindicated in
patients with sick sinus syndrome because of potential
production of symptomatic bradycardia. Concomitant use of
dipyridamole may markedly potentiate the effects of adeno
sine and may precipitate severe hypolension or advanced
conduction delay (1113,19,20) . Hyperemic responses may
MV aD
PV 50	
JACC Vol . 18, No. 3
Scptcmb,r 1991 :71539
Figure 6. Top, Hemodynamic and
coronary flow velocity data records
during infusion of adenosine. A,
Baseline data ; B, after 100 pg/kg of
adenosine ; C, after 150 tcg/kg of
adenosine ; D, after 10 mg of intra
coronary papaverine . The QT inter
val is prolonged in D. No change
occurred after adenosine. Note the
premature ventricular complex oc
curring after papaverine . Bottom,
Hemodynamic and velocity data
record after the single premature
ventricular complex seen in D .
Thirty seconds after the baseline re
cording (above), papavedneinduced
hyperemia (below) demonstrated QT
prolongation with a brief self
terminating run of ventricular tachy
cardia . No adverse effects of adeno
sine were noted in this individual.
Ao = aortic pressure (0 to
200 mm Hg) ; ECG = electrocardio
gram ; MV = mean velocity (velocity
ranges from 0 to 100 cm/s); PA =
pulmonary artery pressure ; PV =
phasic velocity.
be blunted in patients receiving theophylline, which blocks
adenosine receptors (20) .
Adenosine as an alternative to dpyridamole. Pharmaco
logic coronary vasodilation is used with myocardial scintig
raphy to evaluate the presence and prognostic significance of
coronary artery disease (21,22) . Dipyridamole has been a
commonly used agent, increasing coronary blood flow by
blocking cellular uptake of adenosine (23). Adenosine is an
effective alternative agent to dipyridamole (19,24), with a
significantly shorter onset and offset of action . Vernal et al .
(19) performed thallium scintigraphy with intravenous aden
osine (50 to 140 µg/kg per min) in 89 patients and indicated
that the overall sensitivity and specificity for detection of
coronary artery disease were 83% and 94%, respectively .
Despite a high incidence of shortlived side effects (occurring
JACC Vul. III, Nn. 3
Seplumhu, 1991 :71829
Figure 7. Date recorded after a 2
.5mg halos injection of
adenosine . Adenosine is given through a femoral vein fat The
hterk mark) and hyperemia is observed within IS s
recording
speed is increased fruits 10 minis at left to 100 minis at right) .
Transient heart block is seen before peak hyperemic effect .
This example was a worst case demonstration of bean block
after low dose bolus adenosine administration . IV = inirave.
nous : other abbreviations as in Figure 6,
in 83% of patients), adenosineinduced hyperemia for use
with thallium scintigraphy appeared to be a safe and poten
tially useful test in patients unable to exercise (19) . The
frequency of chest pain and other nonspecific symptoms
appeared higher with adenosine than with dipyridamole (25) .
but the symptoms were more rapidly dissipated after cessa
tion of drug infusion. Adenosine also appears to be a more
potent coronary vasodilator than dipyridamole
(24) .
Chest pain and adenosineinduced hyperemia. Chest pain
was a frequent finding in patients with or without coronary
artery disease, but characteristic changes of ischemia as
sessed with the 12lead ECG or pulmonary artery diastolic
pressure measurements did not occur in a consistent man
ner. Chest pain resembling angina pectoris, commonly re
ported in most studies with intravenous adenosine infusions
(1014,26,27), appears in a dosedependent manner (13) . At
very high doses (>200 pg/kg), episodes of first and second
degree AV block preceded the onset of chest pain (13).
Adenosineinduced coronary vasodilation is mediated pre
dominantly by the P, purinergic receptor subtype (20), with
inhibition of the slow calcium inward current or activation of
adenylate cyclase in A, receptors in vascular smooth muscle
(28)
.
However, the specific pharmacologic role in regulating
coronary blood flow remains under study (20) . Intracoronary
adenosine (in doses of I0 s . l0z and 10r' mot/liter for
periods of 2 min) provoked typical anginal chest pain not
elicited during systemic adenosine infusion (14). Aminophyl
line, an adenosine P, receptor antagonist 1291 . reduced the
severity of both adenosine and exerciseinduced chest pain
(14).
indicating that adenosine produced cardiac pain
through receptors that could be partly blocked by amino
phylline and other mcthylxanthines blocking adenosine re
ceptors .
Duration of intravenous adenosine effects . In the current
stud
,
,intravenous adenosine increased coronary blood flow
velocity to its maximum (within 10%; of the papaverine
response) by 20' 25 s, with a return to baseline by 45 ± 20 s
after discontinuation. These results differed somewhat from
earlier reports (10), most likely because of the different sites
and methods of infusion . A submaximal increase in blood
flow at doses >150 Aglkg per min ws observed in one
patient in our study and in 8% of the patients studied by
Wilson et al . (10) with doses >140 pgl`^, . Why adenosine
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failed to produce maximal hyperemia in these individuals is
under study.
Study limitations. Several factors . such as changing distal
arterial pressure . left ventricular scar . hypertrophy or isch
emic dysfunction (for example, anterior hypokinesia) . in
creased contractility, heart rate, left ventricular end
diastolic pressure and altered vascular myogenic tone, can
influence coronary blood flow and, possibly, pharmacologi
cally induced hyperemia (3032) . Adenosine and papaverine
hyperemic responses were also normalized for mean arterial
pressure at the time of measurement to control for blood
pressure variability A majority of factors influencing coro
nary reserve 130.33) should apply to both adenosine and
papaverine flow responses equally, although adenosine may
function through distinct receptor activation unaffected by
papaverine . Within the limits and control of the experimental
design, these factors should have remained relatively con
stant .
The coronary vasodilator reserve ratio had a weaker
although significant correlation compared with mean flow
velocity response for several reasons . First, small changes in
baseline or hyperemia values, or both, have an important
effect when using a ratio calculation . Second, the range of
coronary vasodilator reserve values was narrower than
mean flow velocity . making a greater statistical correlation
more difficult to obtain. When using a coronary vasodilator
reserve ratio >2 .5 as a lower limit of normal, five and four
patients would have had an abnormally low coronary vaso
dilator reserve with adenosine and papaverine, respectively .
The normal coronary vasodilator reserve ratio was lower in
the current study than that reported by Wilson et ai . (10).
This difference has been observed by others (6,7)
and in
earlier studies in our own laboratory
(U17), a finding
attributed to the techniques of flow velocity measurement
and possibly inclusion of more patients who may have
microcirculatory abnormalities (for example, hypertension
or left ventricular hypertrophy) .
Although 12 to 14mg doses of papaverine have been
suggested as optimal (3), 10 mg of papaverine has been the
most commonly used dose to achieve maximal vasodilation
in studies applying these techniques (34).
The highest range
of tolerable effects of adenosine in healthy volunteers was
observed after 140 to 200 pug/kg per min (11,26,27)
. Infusion
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by forearm vein generally produced satisfactory responses .
An earlier time to onset of action and a slightly higher dose
(10 to 20 ysglkg per min) between forearm vein and right atrial
infusion sites have been identified (It) .
Technical problems influencing the accuracy of carouarv
flaw
velocity
hare been described in detail elsewhere
(1 .3,33,34) .
Errors in Doppler velocity measurements are
related to the shape of the velocity profile, the angle of
incidence and position of the sample volume and should be
minimal in our patients with the stable proximal location of
the Doppler catheter. Only coronary flow velocity signals
with clearly demarcated systolic and diastolic phasic wave
forms were accepted for analysis . Previous studies have
demonstrated the linear relation between flow velocity and
measured coronary blood flow (3,15), as well as the high
correlation between subselective and nonselective coronary
Doppler flow velocities (15 .35) in patients without coronary
artery disease. Because of remote risk of vessel closure,
subselective velocity measurements were not performed in
group 2 patients
. Left main coronary artery blood flow
velocity did indicate the proximal velocity responses and,
therefore, reliably reflected comparative effects of papaver
ine and adenosine in this study.
Clinical significance . In most patients, intravenous aden
osine infusion in doses >100 yuglkg per min and low dose
(2.5 mg) bolus injection produces coronary hyperemia nearly
equivalent to that after intracoronary papaverine without
significant
QTc prolongation or propensity for serious ven
tricular arrhythmia. This ultrashortacting agent safely pro
vides an alternative for pharmacologic induction of maximal
coronary hyperemia for studies of the coronary circulation in
patients with or without coronary artery disease .
We thank the 1 . Gerard Mudd Cardiac Catheterization Team and Donna
sander for manuscript preparation . Adenosine was kindly provided by Dr .
Gunnar Nyberg of All Hassle, Inc .. Giileborg, Sweden.
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